ArticleFrontiers in cardiovascular medicine2026
Diplopia as the herald of fulminant myocarditis in undifferentiated connective tissue disease: a case report.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This manuscript describes a rare case of undifferentiated connective tissue disease (UCTD)-associated fulminant myocarditis presenting with isolated diplopia as the sole initial manifestation. A 66-year-old Chinese woman presented with a 17-day history of isolated diplopia. Initial evaluation revealed markedly elevated cardiac enzyme profile and electrocardiographic changes suggestive of acute myocardial infarction. However, coronary angiography revealed no coronary stenosis. Cardiac magnetic resonance imaging (MRI) was consistent with myocarditis. The initial diagnoses included Miller-Fisher syndrome and inflammatory cardiomyopathy. The patient underwent plasma exchange, intravenous methylprednisolone (20 mg daily), and intravenous immunoglobulin (IVIg). Her condition improved. After discharge, oral prednisone was initiated at 20 mg daily, with a weekly taper of 5 mg. However, 12 days after discharge, she was readmitted with abdominal distension. At that time, she also presented with hypotension and ophthalmoplegia. Brain MRI revealed abnormal signals in the medial and lateral rectus muscles bilaterally. Echocardiography revealed a reduced left ventricular ejection fraction (LVEF) of 38%. Endomyocardial biopsy confirmed lymphocytic myocarditis, and serology was positive for anti-SSA/Ro52 antibodies and borderline positive for anti-PL-7 antibody, leading to a diagnosis of UCTD-associated fulminant myocarditis. Treatment with methylprednisolone (60 mg daily) and IVIg resulted in clinical recovery. At three-year follow-up, the patient remained in remission, with complete resolution of diplopia, normalization of cardiac enzyme profile, and no progression to any definite connective tissue disease. This case suggests that isolated diplopia as the sole initial manifestation of UCTD-associated fulminant myocarditis is exceedingly rare. For autoimmune myocarditis, endomyocardial biopsy is crucial to guide treatment. Premature tapering of low-dose corticosteroids led to rapid relapse, highlighting the importance of starting with an adequate dose, tapering slowly, and maintaining the minimal effective dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.